{"id":10002,"date":"2026-05-16T19:55:50","date_gmt":"2026-05-16T16:55:50","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=10002"},"modified":"2026-05-16T19:55:50","modified_gmt":"2026-05-16T16:55:50","slug":"blood-pressure-lowering-across-ckd-stages-meta-analysis-findings","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/blood-pressure-lowering-across-ckd-stages-meta-analysis-findings\/","title":{"rendered":"Blood Pressure Lowering Across CKD Stages: Meta-Analysis Findings"},"content":{"rendered":"<p>Blood Pressure Lowering Across CKD Stages: Meta-Analysis Findings<\/p>\n<p>Source: ReachMD<br \/>\nMay 4, 2026<br \/>\nMeta-analysis published in The Lancet<\/p>\n<p>Key Findings:<br \/>\n* Large individual-participant data meta-analysis including 285,124 participants from 46 randomized trials<br \/>\n* 20.7% had chronic kidney disease (CKD), and 30.2% had type 2 diabetes<br \/>\n* Median follow-up: 4.4 years<br \/>\n* Each 5 mm Hg reduction in systolic BP was associated with ~10% reduction in major cardiovascular events<br \/>\n* Benefit was consistent:<br \/>\n* With or without CKD<br \/>\n* Across CKD stages (including advanced stages)<br \/>\n* Across proteinuria subgroups<br \/>\n* Across baseline BP levels, even &lt;120\/70 mm Hg<br \/>\n* Antihypertensive drug classes showed similar relative effects vs placebo, supporting a BP-driven class- benefit<br \/>\n* Overall conclusion:<br \/>\nCardiovascular benefit of BP lowering is largely preserved across all CKD stages, regardless of renal function severity<\/p>\n<p><a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(26)00367-3\/fulltext\">https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(26)00367-3\/fulltext<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Blood Pressure Lowering Across CKD Stages: Meta-Analysis Findings Source: ReachMD May 4, 2026 Meta-analysis published in The Lancet Key Findings: * Large individual-participant data meta-analysis including 285,124 participants from 46 randomized trials * 20.7% had chronic kidney disease (CKD), and 30.2% had type 2 diabetes * Median follow-up: 4.4 years * Each 5 mm Hg [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10002","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=10002"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10002\/revisions"}],"predecessor-version":[{"id":10003,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10002\/revisions\/10003"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=10002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=10002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=10002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}